Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2021-07-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 418.6KB
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly update from PYC Therapeutics dated July 28, 2021, providing detailed progress on development programs, corporate initiatives, and financial cash flow data for the quarter ended June 30, 2021. It includes a comprehensive Appendix 4C cash flow report, which is a regulatory requirement for entities listed on the ASX (Australian Securities Exchange) to report quarterly cash flows. The document contains substantive financial data, including cash flows from operating, investing, and financing activities, as well as corporate updates and operational progress. This matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial and operational information for a period shorter than a full fiscal year. It is not merely an announcement or a brief summary but includes detailed financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2021
2021-07-27 English
Commencement of Larger Animal Studies for Lead Program 2 pages 164.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commencement of larger animal studies for a lead drug candidate by PYC Therapeutics. It discusses preclinical development stages, expected data release timelines, and plans for an Investigational New Drug (IND) application submission. There are no financial statements, regulatory filings, or detailed financial data. The content is an update on research and development progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about R&D progress and upcoming milestones, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2021-07-13 English
Change of Auditor 1 page 150.4KB
Regulatory Filings Classification · 95% confidence The document announces a change of auditor for the company, specifying the appointment of a new auditor and the resignation of the previous one. It references compliance with listing rules and regulatory consent but does not contain any financial statements or detailed audit reports. The document is short (1242 characters) and serves as an announcement rather than a full audit report or annual report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2021-06-30 English
VP-002 Program - Technical Presentation 18 pages 887.9KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from PYC Therapeutics Limited, dated June 2021, providing an update on their VP-002 program for Autosomal Dominant Optic Atrophy. It includes extensive scientific and preclinical data, program overview, technology explanation, and future plans. The content is structured as a presentation with slides, disclaimers, and forward-looking statements, typical of investor or corporate presentations. There is no indication that this is an official regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting or dividend announcement. The document is too long and detailed to be a simple announcement or report publication notice. The nature of the content aligns best with an Investor Presentation (IP), which focuses on financials, strategy, and market position, including scientific and business updates for investors.
2021-06-28 English
New U.S. Headquarters, and Residency at JLABS 2 pages 168.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the establishment of a new U.S. headquarters for PYC Therapeutics and related strategic developments. It contains no financial statements, regulatory filings, or detailed financial data. It is not an annual or interim report, earnings release, or any form of audit or management report. It is a corporate announcement about operational expansion and team growth. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate update, which corresponds to Regulatory Filings (RNS).
2021-06-14 English
Application for quotation of securities - PYC 6 pages 28.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and whether the securities are part of an employee incentive scheme. The document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares following option exercises. It does not contain financial statements or performance data, nor is it a report or presentation. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2021-06-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.